Biography

Professor Bruno Gander is Senior Scientist at the Institute of Pharmaceutical Sciences at Eidgenössische Technische Hochschule (ETH [Swiss Federal Institute of Technology]) Zürich (part of Galenical Pharmacy Group). He studied pharmacy at the ETH Zürich and after an industrial training placement in Galenical research and development at Novartis, he gained his PhD at the University of Geneva, Switzerland and the Purdue University, USA.
He worked as a postdoctoral researcher at the Department for Pure and Applied Chemistry at the University of Strathclyde, UK, before becoming a senior scientist in Galenical Pharmacy at the University of Geneva. He completed his habilitation in 1999 in pharmaceutical technology and dosage forms.
Professor Gander's research focuses on biodegradable delivery systems for drugs and antigens. His therapeutic areas of interest for these delivery systems encompass infections, cancer, bone fracture healing, peripheral nerve guidance and regeneration, and vaccination with established (tetanus, diphtheria, Hib) and newer (malaria) immunogens. He is a member of the editorial board of several scientific journals, and is also a member of the expert group of the Galenical Pharmacy of the Swiss Federal Pharmacopoeia Commission.